February 2008
Worldwide Biotech;Feb2008, Vol. 20 Issue 2, p7
Trade Publication
The article details the European growth strategy of Abiomed Inc. The company plans to establish recovery as the goal for patients experiencing acute cardiac events. The company's portfolio of circulatory care products including Impella, iPulseTM and AB5000 are approved in 27 European Union nations through CE-Mark approval, and Impella is now approved in over 40 countries outside the U.S.


Related Articles

  • Medical Management of Advanced Heart Failure. Nohria, Anju; Lewis, Eldrin; Stevenson, Lynne // JAMA: Journal of the American Medical Association;2/6/2002, Vol. 287 Issue 5, p628 

    Presents a study to review medical therapy for advanced heart failure as of February 6, 2002. Context; Objective; Data sources; Study selection; Data extraction; Data synthesis; Conclusion that management of advanced heart failure is based more on consensus than on randomized trials, and that...

  • Heart Pump Approved for Permanent Use.  // FDA Consumer;Jan/Feb2003, Vol. 37 Issue 1, p5 

    The U.S. Food and Drug Administration (FDA) has approved a heart assist pump to be implanted permanently in certain terminally ill patients who are not eligible for heart transplant. The device, called HeartMate, is a left ventricular assist device (LVAD) made by Thoratec Corporation of...

  • Effect of Carvedilol on Survival in Severe Chronic Heart Failure. Packer, Milton; Coats, Andrew J.S.; Fowler, Michael B.; Katus, Hugo A.; Krum, Henry; Mohacsi, Paul; Rouleau, Jean L.; Tendera, Michal; Castaigne, Alain; Roecker, Ellen B.; Schultz, Melissa K.; Staiger, Christoph; Curtin, Ellen L.; DeMets, David L. // New England Journal of Medicine;05/31/2001, Vol. 344 Issue 22, p1651 

    Background: Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure. Methods: We evaluated 2289 patients who had symptoms of heart failure at rest or on minimal exertion,...

  • Influence of socioeconomic deprivation on the primary care burden and treatment of patients with a diagnosis of heart failure in general practice in Scotland: population based study. McAlister, F. A.; Murphy, N. F.; Simpson, C. R.; Stewart, S.; MacIntyre, K.; Kirkpatrick, M.; Chalmers, J.; Redpath, A.; Capewell, S.; McMurray, J. J. V. // BMJ: British Medical Journal (International Edition);5/8/2004, Vol. 328 Issue 7448, p1110 

    Objectives To examine whether there are socioeconomic gradients in the incidence, prevalence, treatment, and follow up of patients with heart failure in primary care. Design Population based study. Setting 53 general practices (307 741 patients) participating in the Scottish continuous...

  • NSAIDs, Heart Failure Don't Mix.  // Clinician Reviews;Mar2009, Vol. 19 Issue 3, p6 

    The article discusses a study on the link between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in chronic heart failure and the increased mortality and cardiovascular morbidity. It references a study by G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom et al which was published in...

  • Antithrombotic therapy may prevent sudden coronary death.  // Modern Medicine;Jul97, Vol. 65 Issue 7, p51 

    Presents an abstract of the study `Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure,' by D.L. Dries, M.J. Domanski, M.A. Waclawiw et al published in the April 1, 1997 issue of the `American Journal of Cardiology.'

  • SURVIVING CARDIAC ARREST. Metcalf, Eric; Harrar, Sari // Prevention;Apr2002, Vol. 54 Issue 4, p172 

    Discusses the use of selective aortic arch perfusion to help treat patients who have gone into cardiac arrest, and discusses how the use of this treatment by emergency medical technicians could keep patients alive longer.

  • Investigational Positive Inotropic Agents for Acute Heart Failure. Tamargo, Juan; Caballero, Ricardo; Gómez, Ricardo; Barana, Adriana; Amorós, Irene; Delpón, Eva // Cardiovascular & Haematological Disorders - Drug Targets;Sep2009, Vol. 9 Issue 3, p193 

    Acute heart failure (AHF) represents a major public health problem due to its high prevalence, high rates of mortality and readmissions and significant healthcare costs. Patients with AHF and low cardiac output represent a small subgroup of patients with very high mortality rates that require...

  • Primacor.  // Royal Society of Medicine: Medicines;2002, p451 

    The article presents information on the primacor which is a proprietary, prescription-only preparation of the phosphodiesterase inhibitor milrinone. The drug can be used, in the short term, in heart failure, especially where other drugs have not been successful. It is available in a form for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics